Corporativo Neomedica has completed the sale of a majority stake to Ascendis Capital

April 2026 — Corporativo Neomedica has completed the sale of a majority interest to Ascendis Capital. The transaction represents a significant milestone for the company, with the partnership expected to accelerate growth and support its continued expansion into additional therapeutic verticals.

Corporativo Neomedica is a leading Mexican distributor of medical devices and specialized supplies, with more than 30 years of experience serving public and private hospitals, physicians and specialized distributors nationwide. The company offers surgical instruments, wound care products and laparoscopic equipment, among other medical products. In 2025, Corporativo Neomedica reported revenue of US$11.7 million and an EBITDA margin of 19.6%, reflecting strong profitability and operational efficiency.

Ascendis Capital is a Mexico-based investment platform focused on acquiring and scaling lower middle-market companies. The firm invests in established businesses with strong operating fundamentals and growth potential, leveraging an active, hands-on approach to value creation. Ascendis Capital targets companies with operations in Mexico and the USA, supporting their expansion across North America. The firm focuses on selected industries, including healthcare, industrials, education and business services, partnering with management teams to drive operational improvements and long-term growth.

Our role in the transaction

Oaklins’ team in Mexico acted as the exclusive sell-side advisor to the shareholders of Corporativo Neomedica in their sale of a majority stake to Ascendis Capital.